Evidence map›Paper›PMID 35221968›Full record

ArticleCase reports in oncology

Quantitative Analysis of Immune-Reactive Cells among Leukocytes Is Useful for the Diagnosis of Drug Eruptions Caused by Bexarotene.

Hiromu Chiba, Yumi Kambayashi, Kentaro Ohuchi, Ryo Amagai, Erika Tamabuchi, Akira Hashimoto, Taku Fujimura

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Case reports in oncology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Hiromu ChibaDepartment of Dermatology, Tohoku University Graduate School of Medicine, Sendai, Japan.
Yumi KambayashiDepartment of Dermatology, Tohoku University Graduate School of Medicine, Sendai, Japan.
Kentaro OhuchiDepartment of Dermatology, Tohoku University Graduate School of Medicine, Sendai, Japan.
Ryo AmagaiDepartment of Dermatology, Tohoku University Graduate School of Medicine, Sendai, Japan.
Erika TamabuchiDepartment of Dermatology, Tohoku University Graduate School of Medicine, Sendai, Japan.
Akira HashimotoDepartment of Dermatology, Tohoku University Graduate School of Medicine, Sendai, Japan.
Taku FujimuraDepartment of Dermatology, Tohoku University Graduate School of Medicine, Sendai, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Bexarotene is a third-generation retinoid X receptor-selective retinoid that has been approved for use in the treatment of cutaneous T-cell lymphomas (CTCLs). Since the objective response rate of bexarotene is relatively high, with no racial differences, bexarotene can be administered to patients with phototherapy-resistant early CTCL as one of the first-line therapies in real-world clinical practice. Although various adverse events caused by bexarotene have been reported, there have been no reports of drug eruptions caused by bexarotene. One of the possible reasons is that it is difficult to distinguish a drug eruption from recurrence of CTCL, histologically. In this report, drug eruptions in 2 patients with CTCL treated with bexarotene diagnosed by quantitative analysis of immunohistochemical staining by digital microscopy are described.

Indexed as

BexaroteneCutaneous T-cell lymphomaDrug eruptionQuantitative analysis of tumor-infiltrating lymphocytes

Identifiers

PMID35221968
PMCPMC8832245

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.